SCHEMBL1771503

SCHEMBL1771503

O=C(CNS(=O)(=O)c1ccc2ccccc2c1)NO

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.67
MEP1B Q16820 7/20 0.64
MMP1 P03956 5/20 0.64
MMP2 P08253 4/20 0.64
MMP13 P45452 4/20 0.64
MMP14 P50281 4/20 0.64
MMP9 P14780 2/20 0.64
ADAM17 P78536 2/20 0.64
MMP3 P08254 1/20 0.64
MMP7 P09237 1/20 0.64
MMP8 P22894 1/20 0.64
MMP12 P39900 1/20 0.64
ADAMTS4 O75173 3/20 0.63
ADAMTS5 Q9UNA0 3/20 0.63
KAT6A Q92794 2/20 0.61
PKM P14618 1/20 0.59
ALDH1A1 P00352 1/20 0.58
TPSAB1 Q15661 1/20 0.58
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6438335 0.84 ALDH1A1 (0.69) CTSSMMP1MMP12KAT6APKM
SCHEMBL6848743 0.83 KAT6A (0.63) CTSSKAT6APKMALDH1A1TPSAB1
SCHEMBL8318684 0.83 CTSS (0.65) CTSSKAT6APKMALDH1A1TPSAB1
SCHEMBL8954769 0.83 KAT6A (0.63) CTSSKAT6APKMALDH1A1TPSAB1
Hydrochloric Acid SCHEMBL27487670 0.82 KAT6A (0.61) CTSSKAT6APKMALDH1A1TPSAB1
Hydrochloric Acid SCHEMBL6791749 0.81 TPSAB1 (0.70) CTSSKAT6APKMALDH1A1TPSAB1
SCHEMBL2553981 0.80 MEP1B (0.81) MEP1BMMP1MMP2MMP13MMP14
SCHEMBL14045828 0.79 ALDH1A1 (0.59) CTSSKAT6APKMALDH1A1TPSAB1
SCHEMBL6791372 0.79 ALDH1A1 (0.77) CTSSKAT6APKMALDH1A1TPSAB1
SCHEMBL4926629 0.78 MEP1B (0.53) CTSSMEP1BMMP1MMP2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2008-10-30 US claimed
US-8841291-B2 Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors NOVARTIS AG (CH) 2014-09-23 US disclosed
US-8841291-B2 Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors NOVARTIS AG (CH) 2014-09-23 US disclosed
US-20140031399-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS NOVARTIS AG (CH) 2014-01-30 US disclosed
US-20140031399-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS NOVARTIS AG (CH) 2014-01-30 US disclosed
CN-102143942-A Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors NOVARTIS AG 2011-08-03 CN disclosed
US-20110112076-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS NOVARTIS AG (CH) 2011-05-12 US disclosed
US-20110112076-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS NOVARTIS AG (CH) 2011-05-12 US disclosed
EP-2318361-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS Novartis AG (CH) 2011-05-11 EP disclosed
WO-2010007027-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS NOVARTIS AG (CH) 2010-01-21 WO disclosed
WO-2010007027-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS NOVARTIS AG (CH) 2010-01-21 WO disclosed
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2008-10-30 US disclosed
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2007-03-22 US disclosed
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2007-03-22 US disclosed
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 CTSS 2464/4885MEP1B 3107/4885MMP1 387/4885
US-20110112076-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS MMP13, MMP11, MMP14 CTSS 122/4885MEP1B 1085/4885MMP1 16/4885
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 CTSS 2571/4885MEP1B 3118/4885MMP1 510/4885
US-20140031399-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS MMP13, MMP11, MMP14 CTSS 121/4885MEP1B 1137/4885MMP1 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.